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Abstract: Microbial sharing between humans and animals has been demonstrated in a variety of
settings. However, the extent of microbial sharing that occurs within the healthcare setting during
animal-assisted intervention programs is unknown. Understanding microbial transmission between
patients and therapy dogs can provide important insights into potential health benefits for patients,
in addition to addressing concerns regarding potential pathogen transmission that limits program
utilization. This study evaluated for potential microbial sharing between pediatric patients and
therapy dogs and tested whether patient–dog contact level and a dog decolonization protocol
modified this sharing. Patients, therapy dogs, and the hospital environment were sampled before
and after every group therapy session and samples underwent 16S rRNA sequencing to characterize
microbial communities. Both patients and dogs experienced changes in the relative abundance
and overall diversity of their nasal microbiome, suggesting that the exchange of microorganisms
had occurred. Increased contact was associated with greater sharing between patients and therapy
dogs, as well as between patients. A topical chlorhexidine-based dog decolonization was associated
with decreased microbial sharing between therapy dogs and patients but did not significantly affect
sharing between patients. These data suggest that the therapy dog is both a potential source of and a
vehicle for the transfer of microorganisms to patients but not necessarily the only source. The relative
contribution of other potential sources (e.g., other patients, the hospital environment) should be
further explored to determine their relative importance.
Keywords: microbiome; animal-assisted interventions; hospital-associated pathogens; patient safety
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1. Introduction
Animal-assisted intervention (AAI) therapy, the involvement of animals in alternative
or complementary treatment, can improve the physical, mental, and social functions of
patients within the healthcare setting. AAI has been widely implemented in a range
of physio-social conditions in various settings in healthcare facilities and is becoming
increasingly popular, especially for pediatric patients. AAI is an umbrella term that
encompasses animal-assisted therapy (programs with a set clinical outcome), animal-
assisted education (programs with a set educational/developmental outcome), and animal-
assisted activities (programs without a pre-specified outcome) [1,2]. The most commonly
reported patient benefits include a reduction in patients’ requirement for pain medication,
enhanced socialization, and reduced stress and anxiety [3–6]. Conversely, the potential risks
of incorporating animals into a hospital setting, where patients with decreased immune
function are treated, must be considered. Nosocomial transmission of infectious disease
agents, such as methicillin-resistant Staphylococcus aureus (MRSA), is a serious problem
exacerbated by close contact and antimicrobial selective pressure inherent to healthcare
settings, and we were concerned that dogs involved in AAI—for this paper, termed therapy
dogs—may serve as mechanical vectors of transmission. Many common nosocomial
pathogens, including MRSA and Clostridioides difficile, are zoonotic, in that they can be
carried on animals and transmitted to humans [7–9]. While it is clear that therapy dogs can
carry common hospital-associated pathogens [10–12], evidence is lacking on whether dogs
transmit these microbiota to patients.
Microbes, including pathogens, function in the context of a more global microbial
community, and other non-pathogenic microbiota may similarly be transmitted during
these AAI sessions. Specifically, dogs have unique compositions of their nasal, dermal, and
gastrointestinal microbial communities [13–15], which, compared to humans, could result
in a distinct ability to acquire, carry, and/or spread hospital-associated pathogens. These
distinct microbial communities could also uniquely influence the microbial composition
of individuals that interact with the dogs, in a way that is fundamentally different from
contact with other people or objects in the environment. This circumstance is best illustrated
by data demonstrating the microbial shifts in humans resulting from pet ownership; pet
owners often have more diverse microbial compositions that are more frequently shared
between them [16,17]. Early-life pet ownership is associated with decreased incidence of
immune dysfunction, and exposure to diverse microbes from farm environments, including
animals, is protective against the development of asthma in children [18–21]. However,
these studies focus on chronic exposure from living with animals and pets. It is uncertain if
these same microbial shifts will occur with transient exposure of patients to a therapy dog,
which, in our setting, was often less than one hour.
This study aimed to explore the potential for microbial sharing between pediatric
patients, therapy dogs, and the hospital environment during animal-assisted intervention
programs. We hypothesized that therapy dogs could serve as intermediary mechanical
vectors in the transmission of microbes between the hospital environment and patients,
and interaction with the therapy dog would increase patients’ risk of microbial exposure
(Figure 1). We further examined whether the level of contact between patients and therapy
dogs modifies this microbial sharing. This study used a topical antiseptic treatment on
the therapy dog as a targeted intervention to mitigate potential risks from exposure to
infectious agents to patients participating in AAI. We secondarily hypothesized that this
topical disinfectant, aimed at decreasing the bacterial colonization in the therapy dog,
would have downstream effects on microbial composition in patients. Improving our
understanding of microbial dynamics that occur during an AAI session will contribute
to our knowledge base regarding human–animal microbial exchange research in a novel
setting and have practical implications for AAI program implementation.
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Figure 1. Microbial pathways during animal-assisted intervention programs.
2. Methods
2.1. Experimental Design and Sample Collection
This study was conducted at a pediatric oncology outpatient unit in a mid-Atlantic
hospital between July 2016 and May 2017. The study protocol was approved by all
applicable institutional review boards, institutional animal care and use committees, and
scientific review committees prior to data collection. The therapy dog and handler were
scheduled for one hour in a shared space, during which multiple patients interacted with
the dog at the same time. Microbial samples were collected from the nasal mucosa of
pediatric patients and therapy dogs with a sterile flocked swab (Puritan, Guilford, ME,
USA) before and after the AAI visit, as well as the shared floor space with a vacuum dust
filter [22]. Trained research staff performed all sample collection. During the visit, we
observed interactions of the study participants with the dog, recording the total duration
and frequencies of certain behaviors (petting, hugging, etc.). Blank sterile flocked swabs
were collected at every visit as a negative control. Sample swabs were stored at −80 ◦C
until processing.
The therapy dog team, consisting of the dog and its handler, completed two obser-
vational control visits abiding by established hospital protocol, then crossed over to two
intervention visits with modifications to the hospital therapy dog protocol, as shown in
Supplemental Figure S1. Prior to the first intervention visit, the handler was given a 4%
chlorhexidine-based veterinary prescription shampoo (DUOXO Ceva, Libourne, France) to
use 24 h before the study visit. During the therapy visit, the dog was wiped down along
the head and back, the “petting zone”, with 3% chlorhexidine wet cloths (DUOXO Ceva,
Libourne, France) every 5 to 10 min.
2.2. Laboratory Processing
2.2.1. 16SS rRNA Gene Amplification and Sequencing
Sample swabs and vacuum filter dust were thawed prior to DNA extraction. DNA
sequencing was performed as previously described [16]; see also Supplemental Methods for
additional details. For each set of extractions, one blank swab exposed to laboratory air was
processed as a negative laboratory control. Prior to sequencing, the total DNA concentration
was obtained from a Qubit instrument, and the 16S rRNA gene copies per unit DNA were
evaluated using quantitative PCR. The V1-3 region of the 16S rRNA gene was amplified
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using barcoded primers (27F, 534R) for the Illumina platform as previously described [23].
Sequencing was performed on the MiSeq instrument (Illumina, San Diego, CA, USA)
using 300 base paired-end chemistry at the University of Pennsylvania Next Generation
Sequencing Core. Microbial Mock Communities B (Even-Low v5.1, BEI Resources, NIAID
NIH HMP) were amplified and sequenced as positive controls.
2.2.2. Bioinformatics and Quality Control
QIIMEv2.7 was used for paired-end read assembly and quality filtering for the se-
quences from all samples [24]. The DADA2 plug-in for QIIME2.7 was used to remove
chimeric sequences and sequences greater than 300 bp in length and to cluster sequences
into amplicon sequence variants (ASVs) [25]. ASVs were matched to phylogeny using the
mafft program for multiple masked sequence alignment [26] and FastTree to generate a
phylogenetic tree from the masked alignment [27]. Taxonomy assignment used a naïve
Bayes classifier [28] that was trained on our dataset (trimmed to 300 bp and matched to
our primers), applying Greengenes v13.8 99% OTU match [29]. Taxonomic classification
was confirmed by comparing the identification of the known Mock Community samples.
For quality control purposes, suspected contaminants were identified and removed from
the resulting feature table using the ‘decontam’ R package, based on the prevalence of
taxa in the negative controls and the frequency of taxa as a function of the total DNA
concentration and the 16S rRNA copies from qPCR [30]. Contaminants were identified
independently at each processing step (field sampling, DNA extraction, and sequencing)
and were sequentially removed. Information on the sequencing library and quality control
measures can be found in Supplemental Table S1a,b.
2.3. Statistical Analysis
Statistical analysis was performed in RStudio v1.1.423 [31]. To maintain the maximum
number of samples for comparison, the sequencing data were not rarefied for statistical
analysis [32,33]. Taxa tables, and matching phylogeny and taxonomy, were analyzed using
the phyloseq pipeline to calculate alpha and beta diversity metrics [32]. The primary
analysis was the change in microbial composition comparing pre- and post-visit overall
and by host (human and dog), then stratifying by contact level and visit type (control
versus intervention). Differential abundance of specific taxa between groups was analyzed
using DESeq2 [34]. The Kruskal–Wallis nonparametric one-way analysis of variance test
examined differential alpha diversity between all groups, and the Wilcoxon rank-sum
test was used for pair-wise comparisons between groups; both tests were adjusted for
multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR) correction.
To test which factors were most important in determining microbial composition, analyses
were performed using the non-parametric permutational multivariate analysis of variance
(PERMANOVA) with weighted and unweighted UniFrac distance metrics.
3. Results
3.1. Study Population and Samples
A total of four dogs were studied over 13 AAI visits (2–4 visits per dog team), with
five (38%) being intervention study visits. Forty-five unique pediatric oncology subjects
enrolled in the study (Table 1), with a mean age of 11.7 years old (SD 4.7). Four participants
re-enrolled in the study, resulting in data from 49 study participants. Each therapy visit had
a mean of 3.8 participants (SD 1.4, range 2–6). Thirty-nine participants (79.6%) reported
having a pet at home, with 30 (61.2%) having a dog.
Individual contact behaviors and total patient–dog interaction times are presented
in Supplemental Table S2. The frequency of key behaviors and total time spent with the
therapy dog were aggregated to create an ordinal contact score. The median contact score
was used as a threshold to create a binary contact level of “High” or “Low” contact. Fifty-
one percent of patients were classified as “High” contact, and this was evenly distributed
across control and intervention visits.
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A total of 129 sample swabs were collected for microbial analysis (Table 1). An
additional 33 samples were processed for microbiome quality control. Swab samples were
not collected from eight participants due to either the patient’s fear of the swabbing process
or scheduling conflicts. Two subjects did not have pre-visit culture swabs collected, and
three subjects did not have post-visit swabs collected.
Table 1. Study population and samples.
All Visits Control Visits Intervention Visits
Study Population
Patients N (% Total) N (% Total)
N total sampled 49 *45 26 (53%) *23 23 (47%) *22
Male (%) 31 (63%) 15 (58%) 16 (69%)
Age (y), mean (range) 11.68 (1.9–20.4) 11.07 (1.9–18.4) 12.41 (3.5–20.4)
High Contact (%) 25 (51%) 12 (46%) 13 (56%)
Visits N (% Total) N (% Total)
Total 13 8 (62%) 5 (38%)
Patients per visit, mean
(range) 3.77 (2–6) 3.25 (2–5) 4.6 (3–6)
Therapy Dogs
N Unique Dogs 4
Male (%) 1 (25%)
Age (y), mean (range) 6.43 (1.5–12)
Samples
From Patients 79 43 (54%) 36 (46%)
From Dogs 26 16 (62%) 10 (38%)
From Environment 24 14 (58%) 10 (42%)
Total Samples 129 73 (57%) 56 (43%)
Field Blanks 12 7 (58%) 5 (42%)
Laboratory Controls 21
Total Controls 33
* 45 patients with microbial samples collected, 23 in control and 22 in intervention.
3.2. Relative Abundance
The abundance of microorganisms differed across both host and sample location;
Figure 2A shows the percent relative abundance of the top 25 most abundant genera.
Certain bacterial species had significantly different abundance when comparing across
sites, including Staphylococcus species in the nasal samples of both pediatric subjects and
dogs (Figure 2). Subject and dog nasal samples had similar microbial compositions, with
Staphylococcus species being dominant, but dog nasal samples had a greater abundance
of Moraxella compared to the subjects’ greater abundance of Streptococcus. These data are
summarized in Supplemental Table S3.
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Figure 2. Relative abundance of top 20 genera by (A) Sample Host and Site, and within (B) Patients in Control Visits and (C)
Patients in Intervention Visits. *** Benjamini–Hochberg adjusted p-values < 0.001 for differential abundant genera using a
negative binomial model (DESeq) between sample sites. Within patients (B and C): blue *** = higher in post samples, red
*** = higher in pre samples, Mean total DNA concentration in patients in control = 6.28, in intervention = 4.42 (ng/uL),
Mean qPCR 16S gene copies in patients in control = 22,254, in intervention = 8691 (/uL DNA).
The degree of alteration of patients’ microbial communities varied with contact level
and visit type (Figure 2b,c). Within control visits, subjects with low contact had a higher
abundance of Streptococcus species after the visits compared to before. Subjects in control
visits with high contact had a higher abundance of Moraxella species, both pre- and post-
visit, compared to low-contact subjects in control visits. In contrast, there was no difference
in the abundance of any genera between pre- or post-visit samples in high-contact subjects.
Within the intervention visits, both high- and low-contact subjects had greater abundance
of Streptococcus species before the visit and greater abundance of Staphylococcus species
after the visit, specifically S. epidermidis and not S. aureus (Supplemental Figure S2).
3.3. Alpha Diversity
Alpha rarefaction curves are presented in Supplemental Figure S3. Alpha diversity
significantly differed between hosts (humans versus dogs versus environment), as mea-
sured by the observed total taxa, Shannon, and Faith’s Phylogenetic metrics (Wilcoxon
rank-sum test p < 0.001). This was a consistent observation when stratifying by pre- or
post-visit and by control or intervention visit type.
When examining individual-level changes in alpha diversity that occur during a
therapy visit, in high-contact subjects, there was an overall increase in within-sample
diversity during control visits and an overall decrease during intervention visits; either no
difference or the opposite difference occurred in low-contact subjects (Figure 3A,B). The
change in alpha diversity between pre- and post-visit samples was significantly different
in control versus intervention visits in high-contact patients when measured with Faith’s
metric (Kruskal–Wallis p < 0.05), but not the Shannon metric or observed total taxa. A
similar significant effect could be seen in therapy dog samples when using Faith’s metric
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(Kruskal–Wallis p < 0.01), with an overall increase in alpha diversity following control visits
and a decrease following intervention visits (Figure 3D–F).
Figure 3. Alpha diversity by sample host and site, and within patient samples (A) Total Taxa in Patients (B) Shannon
Diversity in Patients (C) Faith’s Diversity in Patients (D) Total Taxa in Dogs and Environment, (E) Shannon Diversity in
Dogs and Environment and (F) Faith’s Diversity in Dogs and Environment. Thin lines = within-subject changes, bold
lines = aggregated group means, ** Kruskal–Wallis test p < 0.05 for median difference in change in alpha diversity level
(post-pre) in control vs. intervention (in high-contact patients and dogs).
3.4. Beta Diversity
3.4.1. Beta Diversity Distribution
Supplemental Figure S4 shows the overall distribution of samples in principal coor-
dinate analysis plots for both unweighted and weighted UniFrac beta diversity metrics,
by hosts (pediatric subjects, dog, or hospital environment), site, and pre- and post-visit
status. Loose clustering was observed by host and sample site, but not by sample timing
(pre vs. post). Clustering was also not observed by individual subject or visit date. Overall,
the axes accounted for a maximum of 7.8% variation in unweighted UniFrac and 33.5%
variation in weighted UniFrac.
3.4.2. Beta Diversity Distance
Pediatric subjects were more similar to other subjects after the visits, as evidenced
by their reduced microbial composition beta diversity distance (PERMANOVA pre vs.
post FDR-p < 0.001). Patients were also more similar to therapy dogs after the visits
(PERMANOVA pre vs. post FDR-p < 0.001). See example calculations in Supplemental
Figure S5, and results in Supplemental Figure S6 and Supplemental Table S4.
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Subjects with high contact were more similar to other subjects (Figure 4A) and to the
therapy dog (Figure 4C) after the visits, than to low-contact subjects (unweighted UniFrac
metric PERMANOVA FDR-p = 0.0001–0.0003). The same pattern was observed in both
control and intervention visits. Using a weighted UniFrac metric, high-contact subjects
were more similar to other subjects in control visits (p = 0.0005) but not in intervention
visits (Figure 4B). The reverse trend was observed between patients and the dog, with both
high- and low-contact patients more similar in microbial composition to the therapy dog
following intervention visits (p = 0.0001, 0.0005) but not control visits (Figure 4D).
Figure 4. Beta distance for microbial composition difference, by contact level and visit type (post–pre visit) (A) Unweighted
UniFrac Distance Kid to Kid (B) Weighted UniFrac Distance Kid to Kid (C) Unweighted UniFrac Distance Kid to Dog, and
(D) Weighted UniFrac Distance Kid to Dog. PERMANOVA model p-value results for difference in microbial composition
beta distance between patients pre- compared with microbial composition beta distance between patients post-visit (kid-kid)
or difference in microbial composition beta distance between patients and therapy dogs pre- compared with microbial
composition beta distance between patients and therapy dogs post-visit (kid-dog), within each stratification (visit type and
contact level). Refer to Supplemental Figures S3 and S4 for example calculations and pre/post distances, bold FDR-corrected
p < 0.005.
4. Discussion
This study explored microbial transmission among pediatric oncology subjects and
therapy dogs in a hospital-based AAI program. This study is the first to report on sampling
patients, therapy dogs, and the hospital environment before and after a group AAI session,
and the first to explore microbial community dynamics in this setting. Our data suggest
that microbial sharing occurred during the AAI sessions, as microbial compositions of
subjects were altered, both in overall diversity levels and in relative abundance of specific
taxa. We further explored the effect of contact level between patients and therapy dogs
on the alteration of nasal microbial communities following visits, and logically found that
higher contact was associated with increased sharing between subjects and therapy dogs,
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and among subjects. Finally, we determined that an antiseptic decolonization intervention
targeted to the therapy dog modifies the association between contact level and microbial
sharing between therapy dogs and subjects, and between subjects as well.
4.1. Distinct Microbial Profiles and Shifts in Patients and Therapy Dogs
Patients, therapy dogs, and the hospital environment had distinct microbial communi-
ties, as evidenced by differences in the relative abundance of key species, differences in
alpha diversity, and unique clustering of microbial composition in beta diversity. Human
and dog nasal sites tended to be dominated by a few taxa at relatively high abundance
(namely Staphylococcus, Streptococcus, and Moraxella) and had distinct beta diversity clus-
ters on PCoA plots. These data are confirmed by other studies that have evaluated the
microbiome of human skin and nasal samples [35–38].
We observed microbial community shifts in pediatric subjects and therapy dogs during
an AAI therapy session. This was demonstrated by the increase in within-sample alpha
diversity levels in subjects and dogs, more similar microbial compositions between groups
following the visits, and changes in the relative abundance of certain taxa, specifically
Staphylococcus. Beta diversity distance, represented by both unweighted and weighted
UniFrac metric, was calculated as the difference in beta diversity between subject samples
and between subject and dog samples. We then used these metrics as a proxy for the
degree of microbial sharing between these hosts, as these metrics best indicated shifts in
the microbial community structure that occurred during the visits. From these data, we
found that subjects had more similar nasal microbial structure to other subjects and therapy
dogs after the therapy visit compared to before, suggesting that sharing of microbiota
occurred. Such sharing has been demonstrated in other human–animal microbiome studies,
particularly those that evaluated pets in the home [16,17].
4.2. Closer Contact between the Patient and Therapy Dog Increased Microbial Sharing
Our data also suggest that the patient–dog contact level modifies microbial sharing
between subjects and therapy dogs, as well as between subjects. While contact level was
primarily an indicator of the degree of interaction between a subject and a therapy dog,
by extension, it can also reflect the degree of contact that occurs between a patient and the
hospital environment, other patients, and other aspects of the therapy visits (model shown
in Figure 1). In other words, a subject with a high contact score will have higher contact
with the therapy dog, as well as with other patients and individuals, including the therapy
dog handler, and with the hospital environment. Thus, it is logical that high contact with
the therapy dog suggests higher contact with the more general environment, and this was
reflected in our data as being positively associated with increased microbial sharing.
Our data suggest that high-contact patients with more interaction with various aspects
of the therapy programs shared more microbes both with other patients and with the
therapy dogs. This was demonstrated by an increase in within-sample alpha diversity
and more similar beta composition between samples. Interestingly, there were differences
using phylogenetically weighted versus unweighted metrics. Faith’s Phylogenetic alpha
diversity changes were greater than Shannon alpha diversity, suggesting that more phylo-
genetically distinct microbiota are driving the increased alpha diversity in subject samples.
Our unweighted UniFrac distance appeared to show stronger microbial sharing between
high-contact patients and therapy dogs, and among high-contact patients, while the phylo-
genetically weighted UniFrac distance appeared to show significant sharing of rare taxa
among high-contact subjects, but not between humans and dogs.
Taken together, these data suggest that bacteria are shared among humans, and
between humans and dogs, in the AAI setting, but rare bacteria are less commonly shared
between humans and dogs. Our PCoA distributions and relative abundance results,
in addition to previous studies on pet dogs [14,17,39,40], have shown that dogs have
distinct microbial communities compared to humans. These differences could possibly
drive the differences that we observed in weighted beta metrics comparing subject-to-dog
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composition difference to subject-to-subject composition difference. These data therefore
support the hypothesis that dogs can serve as intermediary vectors in the spread of human-
origin common microbiota between patients, but may not be sharing their own unique
microbiota with patients. However, significant sharing of rare taxa occurred among subjects
in the AAI setting. These additional data suggest that the therapy dog is only one potential
pathway by which microbes can be transmitted during these group AAI therapy sessions,
with other pathways shown in Figure 1 potentially being more influential.
4.3. Canine Decolonization Intervention Modified Microbial Sharing
We tested a novel application of a topical chlorhexidine to therapy dogs and assessed
how this canine decolonization intervention influenced microbial sharing between patients
and dogs and among patients. Our data preliminarily demonstrate that the dog microbial
decolonization intervention modifies the observed relationship between contact level and
microbial sharing. The decolonization intervention appeared to have influenced more phy-
logenetically distinct, rare taxa, as different outcomes were obtained using phylogenetically
weighted versus phylogenetically unweighted diversity models. Within the intervention
visits, microbial sharing of common taxa was still observed among subjects and between
subjects and therapy dogs, as evaluated by the unweighted UniFrac distances. However,
unlike in control visits, the weighted UniFrac distances suggest that rare taxa were not
shared among subjects. Thus, the intervention appears to have blocked the sharing of rare,
phylogenetically diverse taxa between humans. High-contact subjects had more signifi-
cantly decreased alpha diversity levels following intervention visits than in control visits,
indicating that our canine-centered decolonization had indirect effects on the microbial
diversity levels of human subject samples. These data are consistent with previous data on
the effects of the hospital built-environment microbiome on patient microbial composition,
and particularly those data regarding the influence of environmental cleaning regimens on
patient microbiota [41–43].
Interestingly, following intervention visits, both high- and low-contact patients ap-
peared to have more similar microbial compositions to therapy dogs, using the phylogenet-
ically weighted UniFrac metric. This contrasts control visits, where subjects of both contact
levels had less similar microbial communities to dogs. This difference is explained less
by microbial sharing, as the effect of the disinfectant intervention on the dog’s microbiota.
The decolonization selectively removes unique dog taxa from the dog itself, perhaps more
easily allowing recolonization with the microbial community of the subjects.
The intervention was also associated with changes in the abundance of specific taxa.
High-contact patients had a higher relative abundance of staphylococcal species following
intervention visits compared to high-contact patients following control visits. This change
was primarily driven by S. epidermidis, a predominant human nasal and skin commensal,
rather than S. aureus, which can be more pathogenic. Because this metric compares relative
rather than absolute abundance within each sample group, it is not surprising that human
commensals are of greater relative abundance in intervention visits than control visits,
since the subjects were exposed to fewer taxa from the therapy dog.
Overall, while the intervention influenced microbial composition, diversity levels, and
sharing among humans, it primarily exerted these effects by modulating the therapy dog’s
microbial composition. If the therapy dog was the only or primary source of microbes
that were transferred to patients during AAI sessions, we would expect to see reduced
sharing of both common and rare taxa between patients and dogs following intervention
visits when the therapy dog pathway is blocked. Since we only see this pattern with
phylogenetically distinct, rare taxa, not common taxa, it appears more likely that the
therapy dog serves as an intermediary point of microbial sharing, rather than a source
of microbes. Thus, the dog is only one of many possible pathways of microbial sharing
(Figure 1), and these other pathways may contribute more to microbial changes seen in
subjects attending AAI visits.
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4.4. Strengths, Limitations, and Future Directions
While designed as a pilot study to assess feasibility, this study expressly targets
microbial transmission that occurs during hospital AAI programs and is the first to report
on sampling multiple components before and after each visit. As such, these data provide a
critical foundation for larger studies in this area. Previous studies have focused exclusively
on carriage in the therapy animal or have assessed aggregated rates of infection diagnosis
in departments with or without AAI programs [11]. By sampling multiple components—
the patients, the therapy dogs, and the hospital environment—we can begin to elucidate
exposure pathways from these individual data points. In addition to our novel sampling
strategy, this is the first study to assess the effect of patient–dog contact on microbial
sharing. Human–animal contact level has been previously described as a risk factor for
the exposure and acquisition of pathogens in the case of pet ownership [44,45]. However,
it was unknown if the same positive association would occur with the transient contact
between patients and therapy dogs. This study also benefits from the novel deployment of
an established canine decolonization procedure, adapted from veterinary clinical protocols
for canine patients with dermatopathologies. The intervention appeared to limit the spread
of the therapy dog’s own unique microbiota to patients, and also reduced the therapy dog’s
role as an intermediary vector in the spread of microorganisms between patients or other
individuals and the hospital environment.
This study does have practical limitations. As a feasibility study in preparation for
a larger infection control trial, including the implementation of the decolonization inter-
vention, it is limited by the small sample size, particularly when considering the number
of unique dogs. While our sampling was fairly extensive, sampling other sites, both on
the subjects and in the hospital environment, as well as other individuals, such as health-
care workers and the handlers, may have provided additional data to support alternative
hypotheses. Multiple pathways depicted in Figure 1 are, in fact, quite challenging to
examine, and blanket statements inferring directionality of transmission from therapy
dogs to patients or vice versa should be taken with appropriate caution. Finally, this
experiment assessed microbial exposure and composition at one time point. Our data do
not address whether the changes observed during the visit will persist and, if so, for how
long. These data also do not support claims regarding the health outcomes related to these
microbial community shifts, particularly related to the exposure of potentially pathogenic
microorganisms and to rare taxa from the therapy dog.
Future work on this topic will expand to studying AAI sessions that involve only one
child per dog, thus providing more controlled insight into potential microbial transmission
pathways and increasing the generalizability of findings to other situations. Studies that
sample within different hospital departments with varying compositions of patients, and
various hospitals, will also be required to increase the generalizability. Lastly, longitudinal
studies are required to explore the temporal stability of these microbial shifts observed in
patients and determine whether it leads to clinically significant outcomes. Such longitudi-
nal studies are especially important when considering the exposure to rare dog taxa, given
that early-life exposure to pets is associated with decreased incidence of allergic and atopic
diseases in children [46,47], and having a diverse microbiome is protective against numer-
ous health outcomes and can be protective against colonization from pathogens [48,49].
If such data suggest that exposure to therapy dogs, even briefly during AAI programs,
can benefit microbial diversity and microbial community resilience over the longer term,
this will be a previously undescribed benefit of AAI and may increase its utilization in
patient care.
5. Conclusions
These findings indicate that, while there is presumed microbial sharing between pe-
diatric patients and therapy dogs, and while the therapy dog has the potential to serve
as an intermediary vector of microbial spread, other potential transmission pathways
(patient-to-patient, and environment-to-patient) also appear to contribute to microbial
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sharing during group AAI visits. Our results also suggest that the therapy dog could be a
source of more unique microbes to patients. As hospital exposure and certain therapies
decrease microbial diversity in patients, therapy dog exposure may provide a novel way to
mitigate this imbalance and transmit potentially beneficial microorganisms that could be
protective against hospital pathogen colonization and infection. This study shows that mi-
crobial community alterations in patients and therapy dogs during these therapy programs
warrant additional research, which will make these programs safer and more sustainable.
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